	US 12,098,127 B2
	Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor
Huijun He, Shanghai (CN); Shenyi Shi, Shanghai (CN); Jianyu Lu, Shanghai (CN); Charles Z. Ding, Shanghai (CN); Lihong Hu, Shanghai (CN); Bin Shi, Shanghai (CN); Wenqian Yang, Shanghai (CN); Jiaqiang Dong, Shanghai (CN); and Tie-Lin Wang, Shanghai (CN)
Assigned to LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., Shanghai (CN); and SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD., Shandong (CN)
Appl. No. 17/295,878
Filed by LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., Shanghai (CN); and SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD., Shandong (CN)
PCT Filed Oct. 17, 2019, PCT No. PCT/CN2019/111624 § 371(c)(1), (2) Date May 21, 2021, PCT Pub. No. WO2020/108154, PCT Pub. Date Jun. 4, 2020.
Claims priority of application No. 201811434915.8 (CN), filed on Nov. 28, 2018.
Prior Publication US 2022/0017463 A1, Jan. 20, 2022
Int. Cl. C07D 209/30 (2006.01)

CPC C07D 209/30 (2013.01) [C07B 2200/13 (2013.01)]

10 Claims

1. A compound of formula (I),